1977557-86-0

SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is the payload of STRO-002[1][2].

[1] Alice Yam, et al. Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereof. Patent. WO2021247798.
[2] De Almeida V, et al. Preclinical activity and safety of STRO-002, a novel ADC targeting folate receptor alpha for ovarian cancer. Gynecologic Oncology, 2018, 149: 50.